MedPharm and Tergus Pharma Merger Forms Topical and Transepithelial CDMO Leader

MedPharm, Ltd., an Ampersand Capital Partners portfolio company, and Tergus Pharma, a Great Point Partners portfolio company, jointly announced today a merger. The combined topical and transepithelial Contract Development and Manufacturing Organization (CDMO) will operate under the MedPharm name, establishing a leading, end-to-end CDMO with robust scientific, clinical trial manufacturing and commercial production capabilities. As part of this transaction, Tergus Pharma CEO Michael Kane has been appointed CEO of MedPharm while Patrick Walsh will continue to serve as Executive Chairman of MedPharm.

Read also – CA-based GrubMarket Acquires Brothers Produce

The merged business is well-positioned as a global leader in delivering a full suite of drug development and manufacturing services to innovators of all sizes focused on advancing topical and transepithelial pharmaceuticals. The strategic combination of Tergus and MedPharm’s capabilities enables commercial production and serialization to existing formulation development, in vitro testing and clinical manufacturing within one integrated organization. Expanded capabilities will also include the development and manufacture of hormone-based and highly potent drugs at the Company’s GMP manufacturing facility in Durham, NC.

Read also – [Funding News] Polystyvert Raises $16M in Series B Funding

Michael Kane commented, “This strategic partnership is an exciting opportunity to deliver extensive pharmaceutical product development resources fueled by a robust team of scientific experts while leveraging our cutting-edge topical GMP facility to seamlessly meet our customers’ commercial production needs. With locations in both the United Kingdom and the United States, we are well positioned to provide exceptional support to our existing and prospective pharmaceutical clients.”

MedPharm Executive Chairman Patrick Walsh added “Pharma clients have been seeking a reliable, integrated service offering for their ophthalmic, topical and transdermal development and manufacturing projects. This merger creates an immediate option with two organizations already well-positioned in the industry.”

Tergus lead investor Great Point Partners will retain a significant minority ownership stake in the newly combined MedPharm, while private equity firms Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership.

About MedPharm

MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models. Well-established as the global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic and ophthalmic delivery, MedPharm has locations in the United Kingdom and United States, including a new 97,000 sq. ft. state-of-the-art facility in Durham, NC and is recognized globally for its regulatory and technical expertise.

About Tergus Pharma

Tergus Pharma is an end-to-end contract service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our 100,000 sq. ft. state-of-the-art facility in Durham, NC. Tergus is the industry leader for topical semi-solids and liquids for skin, nasal, otic, ophthalmic, vaginal, and rectal routes of administration.